Chitosan oligosaccharide powder for knee joint care formulation compound with glucosamine

Chitosan Oligosaccharide | Joint Protection & Osteoarthritis Support

with Glucosamine Synergistic Effect

Unified terminology: chitosan oligosaccharide (COS). Style and structure fully aligned with previous datasheets (immune / glucose metabolism / gut barrier / liver protection). For B2B raw material landing page, technical brochure and joint health formulation design.

---

Chitosan Oligosaccharide

Chitosan oligosaccharide is a low‑molecular‑weight natural oligosaccharide manufactured by controlled enzymatic hydrolysis of chitosan sourced from marine crustacean shells. It features excellent water solubility, high bioavailability and excellent biocompatibility. Extensive in vitro and in vivo research validates its chondroprotective and anti‑inflammatory properties in joint health, and its proven synergistic effect with glucosamine makes it a premium functional ingredient for osteoarthritis care and long‑term joint maintenance. Food grade specification with customizable molecular weight and deacetylation degree is available to match different formulation requirements.

Mechanism of Action

1. Chondroprotective Mechanism of Chitosan Oligosaccharide Alone

1. Suppress synovial inflammation via AMPK activation: COS activates AMPK signaling pathway in synoviocytes, inhibits over‑activation of NF‑κB and MAPK cascades, and downregulates pro‑inflammatory mediators including TNF‑α, IL‑1β, IL‑6, iNOS and COX‑2, thus alleviating synovial swelling, inflammatory infiltration and joint pain in early osteoarthritis progressionPubMed.
2. Protect cartilage extracellular matrix: It downregulates matrix metalloproteinases (MMP‑1, MMP‑3, MMP‑13) that degrade cartilage, reduces the breakdown of type II collagen and proteoglycans, and simultaneously stimulates chondrocyte proliferation to promote cartilage matrix synthesis.
3. Regulate bone remodeling homeostasis: COS upregulates osteoprotegerin (OPG) expression and decreases RANKL level in cartilage tissue, elevates OPG/RANKL ratio, inhibits excessive osteoclast activation and slows subchondral bone degeneration and joint space narrowingPubMed.
4. Antioxidant & anti‑apoptotic effect: Scavenges reactive oxygen species (ROS) in joint tissue, reverses IL‑1β‑induced chondrocyte apoptosis, and maintains chondrocyte viability and cartilage tissue integrityPMC.

2. Synergistic Effect with Glucosamine

1. Complementary dual‑pathway action: Glucosamine serves as the essential biosynthetic precursor of glycosaminoglycans and proteoglycans, providing building blocks for cartilage matrix regeneration; COS focuses on suppressing inflammatory response and blocking cartilage matrix degradation. The combination delivers simultaneous "synthesis promotion + degradation inhibition" effects for superior cartilage maintenance.
2. Enhanced glucosamine bioavailability: COS improves intestinal barrier function and mucosal permeability, promoting the intestinal absorption of co‑administered glucosamine and increasing its systemic bioavailability.
3. Amplified anti‑inflammatory efficacy: Combined administration produces a stronger inhibitory effect on pro‑inflammatory cytokines (IL‑1β, TNF‑α, IL‑6) and C‑reactive protein (CRP) than either ingredient alone, achieving greater relief of joint inflammation and stiffness.
4. Synergistic cartilage homeostasis: Glucosamine drives new cartilage matrix production, while COS protects the newly formed matrix from MMP‑mediated breakdown. Together they sustain cartilage structural integrity and delay osteoarthritis progression more effectively than monotherapy.

Application Research Data

• In vitro synoviocyte study: Chitosan oligosaccharide dose‑dependently activated AMPK in human and rabbit synoviocytes, and suppressed TNF‑α‑induced iNOS and COX‑2 expression via an AMPK‑dependent mechanism, reducing inflammatory mediator release in synovial tissuePubMed.
• ACLT‑induced osteoarthritis rabbit model: Oral administration of COS at 10 mg/kg/day significantly activated synovial AMPK, lowered COX‑2 protein expression, alleviated synovial hyperplasia and inflammatory infiltration, and relieved joint swelling in OA rabbits.
• Rat osteoarthritis model: COS intervention improved cartilage damage grade, upregulated OPG expression, downregulated RANKL, and increased OPG/RANKL ratio in cartilage, indicating protective effect on subchondral bone and cartilage interfacePubMed.
• Mouse OA model (combination with glucosamine): The glucosamine‑COS mixture dose‑dependently decreased serum levels of pro‑inflammatory cytokines IL‑1β, IL‑6, TNF‑α and CRP, while elevating anti‑inflammatory IL‑2. The anti‑inflammatory efficacy of the combination was superior to glucosamine alone in OA mice.
• Formulation application: Incorporated into joint health dietary supplements, the COS + glucosamine formula delivers better improvement in joint stiffness, mobility and daily activity comfort compared to single‑ingredient formulations, and is suitable for long‑term joint maintenance in middle‑aged and elderly populations.

Applications Joint health dietary supplements, osteoarthritis support nutraceuticals, functional foods, sports nutrition products. Available Supporting Documents COA, heavy metal & microbial test reports, FDA factory registration, allergen statement, technical research references.

---

Bullet-Point Compact Version (Product Card / PDF Datasheet)

Chitosan Oligosaccharide

✅ Raw Material Introduction Natural bioactive oligosaccharide from enzymatically hydrolyzed marine chitosan. Low molecular weight, fully water‑soluble with high bioavailability and biocompatibility. Food grade; customizable molecular weight and deacetylation degree. Proven synergy with glucosamine for joint health formulations.

✅ Chondroprotective Mechanism • Activate AMPK pathway, suppress NF‑κB/MAPK, reduce TNF‑α/IL‑1β/IL‑6 and relieve synovial inflammation. • Inhibit MMPs, protect type II collagen & proteoglycans, stimulate chondrocyte proliferation. • Upregulate OPG/RANKL ratio, inhibit osteoclast overactivation and slow joint degeneration. • Scavenge ROS, inhibit chondrocyte apoptosis and maintain cartilage integrity.

✅ Synergistic Effect with Glucosamine • Complementary modes: glucosamine supplies cartilage matrix precursors; COS blocks inflammation & matrix breakdown. • Improves intestinal absorption and bioavailability of co‑administered glucosamine. • Stronger suppression of pro‑inflammatory cytokines and CRP than single ingredient. • Jointly sustain cartilage homeostasis and delay OA progression more effectively.

✅ Application Research Data • In vitro: AMPK‑dependent inhibition of inflammatory mediators in human synoviocytes. • ACLT rabbit OA model: oral COS reduces synovial COX‑2 and alleviates joint inflammation. • Rat OA model: elevates OPG/RANKL ratio and improves cartilage damage grade. • Mouse OA combination study: COS + glucosamine shows superior anti‑inflammatory efficacy vs glucosamine alone. • End‑use: combined formula improves joint stiffness and mobility better than monotherapy.

✅ Applications Joint health supplements, osteoarthritis nutraceuticals, functional foods, sports nutrition ✅ Supporting Documents COA, heavy metal test, microbiological report, FDA registration, research citations.

 

---

VAS pain assessment
In the resting state, the experimental group showed a more significant difference in efficacy with prolonged medication time.
In the active state, there was a significant difference in the early stage, and the experimental group showed better results over time

      WOMAC Osteoarthritis Assessment
      From the three aspects of pain, stiffness, and physical function evaluation, the experimental group gradually   showed more significant functional status with prolonged medication time.